KTRA
Income statement / Annual
Last year (2024), Kintara Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Kintara Therapeutics, Inc.'s net income was -$8.50 M.
See Kintara Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
Period Ended |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
06/30/2015 |
Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Cost of Revenue |
$55.00 K
|
$60.00 K
|
$60.00 K
|
$32.00 K
|
$10.00 K
|
$16.35 K
|
$24.53 K
|
$16.68 K
|
$10.29 K
|
$0.00
|
Gross Profit |
-$55.00 K
|
-$60.00 K
|
-$60.00 K
|
-$32.00 K
|
-$10.00 K
|
-$16.35 K
|
-$24.53 K
|
-$16.68 K
|
-$10.29 K
|
$0.00
|
Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Research and Development Expenses |
$2.66 M
|
$9.31 M
|
$15.17 M
|
$11.82 M
|
$3.63 M
|
$3.66 M
|
$7.13 M
|
$5.00 M
|
$3.36 M
|
$2.56 M
|
General & Administrative Expenses |
$5.79 M
|
$5.49 M
|
$7.51 M
|
$9.76 M
|
$4.51 M
|
$4.74 M
|
$4.04 M
|
$3.32 M
|
$2.85 M
|
$2.17 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$5.79 M
|
$5.49 M
|
$7.51 M
|
$9.76 M
|
$4.51 M
|
$4.74 M
|
$4.04 M
|
$3.32 M
|
$2.85 M
|
$2.17 M
|
Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Operating Expenses |
$8.45 M
|
$14.80 M
|
$22.68 M
|
$21.57 M
|
$8.14 M
|
$8.40 M
|
$11.17 M
|
$8.32 M
|
$6.21 M
|
$4.72 M
|
Cost And Expenses |
$8.45 M
|
$14.80 M
|
$22.68 M
|
$21.57 M
|
$8.14 M
|
$8.40 M
|
$11.17 M
|
$8.32 M
|
$6.21 M
|
$4.72 M
|
Interest Income |
$0.00
|
$137.00 K
|
$14.00 K
|
$120.00
|
$75.25 K
|
$60.70 K
|
$33.24 K
|
$457.00
|
$108.00
|
$363.00
|
Interest Expense |
$0.00
|
$0.00
|
$14.00 K
|
$26.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.09 K
|
Depreciation & Amortization |
$55.00 K
|
$60.00 K
|
$60.00 K
|
$32.00 K
|
$10.00 K
|
$16.35 K
|
$24.53 K
|
$16.68 K
|
$10.29 K
|
$363.00
|
EBITDA |
-$8.40 M |
-$14.74 M |
-$22.62 M |
-$38.15 M |
-$9.12 M |
-$8.03 M |
-$11.11 M |
-$8.07 M |
-$8.85 M |
-$4.72 M |
EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Total Other Income/Expenses Net |
$131.00 K
|
$147.00 K
|
$21.00 K
|
-$16.63 M
|
-$982.00 K
|
$350.28 K
|
$36.35 K
|
$324.16 K
|
-$2.27 M
|
$376.89 K
|
Income Before Tax |
-$8.32 M
|
-$14.65 M
|
-$22.66 M
|
-$38.30 M
|
-$9.13 M
|
-$8.05 M
|
-$11.14 M
|
-$8.08 M
|
-$8.86 M
|
-$4.80 M
|
Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Income Tax Expense |
$76.00 K
|
-$147.00 K
|
-$42.00 K
|
$26.00 K
|
$981.37 K
|
-$639.85 K
|
-$39.46 K
|
-$477.67 K
|
$5.30 M
|
$69.29 K
|
Net Income |
-$8.50 M
|
-$14.65 M
|
-$22.66 M
|
-$38.32 M
|
-$10.11 M
|
-$7.41 M
|
-$11.14 M
|
-$8.08 M
|
-$8.86 M
|
-$4.80 M
|
Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
EPS |
-3.23 |
-9.27 |
-25.8 |
-74.02 |
-48.39 |
-143.87 |
-266.96 |
-335.43 |
-404.86 |
-251.98 |
EPS Diluted |
-3.23 |
-9.27 |
-25.8 |
-74.02 |
-48.39 |
-143.87 |
-266.96 |
-335.43 |
-404.86 |
-251.98 |
Weighted Average Shares Out |
$2.64 M
|
$1.62 M
|
$974.04 K
|
$517.72 K
|
$208.88 K
|
$51.49 K
|
$41.72 K
|
$24.09 K
|
$21.90 K
|
$19.03 K
|
Weighted Average Shares Out Diluted |
$26.35 M
|
$1.62 M
|
$974.00 K
|
$517.72 K
|
$208.88 K
|
$51.49 K
|
$41.72 K
|
$24.09 K
|
$21.90 K
|
$19.03 K
|
Link |
|
|
|
|
|
|
|
|
|
|